Looks like this study has helped confirm the nature of the behaviour of afamelanotide in more details in the wider bode and in the sensitive area of the brain in individuals suffering sudden very traumatic specific events. This increases the depth of scientific understanding and the safety profile, while suggesting it could be feasible useful for other conditions beyond photosensitivity.
Understandable they would not which to processed further at this time with this as a treatment goal. To do so would require them to hire, and equipped labs, with specialists in neurology and other areas, then branch-off additional development pipelines in a very different direction.
Though it is encouraging to see they are willing to consider the wider application beyond the core one of photosensitivite. Two drugs we know very well have shown quite nice results when used to treat conditions they where not originally intended for; Silde-nafil (hyphen required due to google censuring) and Semaglutide.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)